# TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

> **NCT04888546** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 20 (estimated)

## Conditions studied

- Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

## Interventions

- **DRUG:** Anlotinib hydrochloride capsules＋ TQB2450 injection

## Key facts

- **NCT ID:** NCT04888546
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-30
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04888546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04888546, "TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04888546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*